je.st
news
Tag: merck
Merck Announces Increased Quarterly Dividend
2015-11-24 18:35:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the companys quarterly dividend to $0.46 per outstanding share of the companys common stock, up $0.01 from $0.45 per outstanding share paid last quarter. Payment will be made on Jan. 8, 2016, to stockholders of record at the close of business on Dec. 15, 2015. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: increased
quarterly
announces
dividend
Merck Announces Initial Results for KEYTRUDA (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress
2015-11-21 22:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three studies investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in combination with three other immunotherapies epacadostat, IMLYGICTM (talimogene laherparepvec), and ipilimumab in patients with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orAn Phan, (908) 255-6325orInvestors:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
international
research
society
Merck Animal Health Pioneers H3N2 Canine Influenza Vaccine
2015-11-20 22:00:08| Merck.com - Corporate News
Dateline City: MADISON, N.J. Innovative Addition Further Strengthens CIV Product Line Madison, N.J. - In response to the H3N2 canine influenza (CIV) outbreaks that impacted dogs in 241 states, Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the U.S. Department of Agriculture (USDA) has issued a conditional product license for a vaccine to protect against this newly identified strain of CIV. Canine Influenza Vaccine H3N2 will be available to U.S. veterinarians beginning Monday, November 23. Language: English read more
Tags: health
animal
vaccine
pioneers
Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
2015-11-19 12:30:12| Merck.com - Research & Development News
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lillys ALIMTA (pemetrexed for injection) and Mercks KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Language: English read more
Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting
2015-11-16 14:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Merck Advances to Part B of C-CREST Phase 2 Clinical Development Program KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the companys C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens a regimen of grazoprevir1, MK-36822 and elbasvir3; and a regimen of grazoprevir, MK-3682 and MK-84084 in treatment-nave patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
results
studies
meeting
Sites : [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] next »